American Vanguard (AVD) 10-Q 1 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	Apr. 23, 2015
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Trading Symbol	AVD
Entity Registrant Name	AMERICAN VANGUARD CORP
Entity Central Index Key	5981
Current Fiscal Year End Date	-19
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		29,118,994

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Net sales	$66,565	$81,095
Cost of sales	41,915	52,190
Gross profit	24,650	28,905
Operating expenses	24,344	25,199
Operating income	306	3,706
Interest expense	680	631
Interest capitalized	-39	-18
(Loss) income before provision for income taxes (benefit) and loss on equity investment	-335	3,093
Income taxes (benefit) expense	-292	1,016
(Loss) income before loss on equity investment	-43	2,077
Less net loss from equity method investment		-72
Net (loss) income	-43	2,005
Add back net loss attributable to non-controlling interest	94	154
Net income attributable to American Vanguard	51	2,159
Change in fair value of interest rate swaps		136
Foreign currency translation adjustment	-248	51
Comprehensive (loss) income	($197)	$2,346
Earnings per common share-basic	$0	$0.08
Earnings per common share-assuming dilution	$0	$0.07
Weighted average shares outstanding-basic	28,527	28,401
Weighted average shares outstanding-assuming dilution	28,839	28,888

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$6,870	$4,885
Receivables:
Trade, net of allowance for doubtful accounts of $117 and $166, respectively	82,028	86,027
Other	2,784	2,396
Total receivables	84,812	88,423
Inventories	166,981	165,631
Prepaid expenses	14,565	13,415
Income taxes receivable	6,343	5,964
Deferred income tax assets	8,731	8,731
Total current assets	288,302	287,049
Property, plant and equipment, net	49,187	50,026
Intangible assets, net of applicable amortization	98,621	100,211
Other assets	34,606	35,885
Total assets	470,716	473,171
Current liabilities:
Current installments of other notes payable	272	71
Current installments of other liabilities	1,360	1,357
Accounts payable	23,981	20,411
Deferred revenue	4,558	898
Accrued program costs	57,996	52,546
Accrued expenses and other payables	5,729	5,962
Total current liabilities	93,896	81,245
Long-term debt and other notes payable, excluding current installments	85,036	99,455
Other liabilities, excluding current installments	3,022	3,309
Deferred income tax liabilities	28,159	28,159
Total liabilities	210,113	212,168
Commitments and contingent liabilities
Stockholders' equity:
Preferred stock, $.10 par value per share; authorized 400,000 shares; none issued
Common stock, $.10 par value per share; authorized 40,000,000 shares; issued 31,562,678 shares at March 31, 2015 and 31,550,477 shares at December 31, 2014	3,157	3,156
Additional paid-in capital	66,694	66,232
Accumulated other comprehensive loss	-2,218	-1,970
Retained earnings	201,967	202,488
Total stockholders' equity including treasury stock	269,600	269,906
Less treasury stock at cost, 2,450,634 shares at March 31, 2015 and December 31, 2014	-8,269	-8,269
American Vanguard Corporation stockholders' equity	261,331	261,637
Non-controlling interest	-728	-634
Total stockholders' equity	260,603	261,003
Total liabilities and stockholders' equity	$470,716	$473,171

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, except Share data, unless otherwise specified
Allowance for doubtful accounts	$117	$166
Preferred stock, par value per share	$0.10	$0.10
Preferred stock, shares authorized	400,000	400,000
Preferred stock, shares issued	0	0
Common stock, par value per share	$0.10	$0.10
Common stock, shares authorized	40,000,000	40,000,000
Common stock, shares issued	31,562,678	31,550,477
Treasury stock, shares	2,450,634	2,450,634

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (USD $)	Total	Common Stock	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Treasury Stock	AVD Total	Non- Controlling Interest
In Thousands, except Share data
Beginning Balance at Dec. 31, 2014	$261,003	$3,156	$66,232	$202,488	($1,970)	($8,269)	$261,637	($634)
Beginning Balance (in shares) at Dec. 31, 2014	31,550,477	31,550,477				2,450,634
Stocks issued under ESPP (in shares)		24,144
Stocks issued under ESPP	280	2	278				280
Cash dividends on common stock ($0.02 per share)	-572			-572			-572
Foreign currency translation adjustment, net	-248				-248		-248
Stock based compensation	1,427		1,427				1,427
Stock options exercised and grants of restricted stock units (in shares)		-11,943
Stock options exercised and grants and vesting of restricted stock units	-1,245	-1	-1,244				-1,245
Excess tax benefits from share based payment arrangements	1		1				1
Net (loss) income	-43			51			51	-94
Ending Balance at Mar. 31, 2015	$260,603	$3,157	$66,694	$201,967	($2,218)	($8,269)	$261,331	($728)
Ending Balance (in shares) at Mar. 31, 2015	31,562,678	31,562,678				2,450,634

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical) (USD $)	3 Months Ended
	Mar. 31, 2015
Cash dividends on common stock, per share	$0.02

CONDENSED_CONSOLIDATED_STATEME3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities:
Net (loss) income	($43)	$2,005
Adjustments to reconcile net (loss) income to net cash provided by (used in) operating activities:
Depreciation and amortization of fixed and intangible assets	3,954	3,733
Amortization of other long term assets	1,430	1,454
Amortization of discounted liabilities	49	69
Stock-based compensation	1,427	768
Tax benefit from exercise of stock options	-1	-235
Operating loss from equity method investment	0	328
Gain from dilution of equity method investment		-256
Changes in assets and liabilities associated with operations:
Decrease (increase) in net receivables	3,611	-30,940
Increase in inventories	-1,350	-18,629
Increase in prepaid expenses and other assets	-1,301	-3,242
(Increase) decrease in income tax receivable/payable, net	-378	695
Increase (decrease) increase in accounts payable	3,570	-381
Increase (decrease) in deferred revenue	3,660	-2,309
Increase in other payables and accrued expenses	5,214	5,050
Net cash provided by (used in) operating activities	19,842	-41,890
Cash flows from investing activities:
Capital expenditures	-1,522	-1,816
Net cash used in investing activities	-1,522	-1,816
Cash flows from financing activities:
Net (payments) borrowings under line of credit agreement	-14,400	47,450
Payments on other long-term liabilities	-351	-356
Tax benefit from exercise of stock options	1	235
Increase in other notes payable	200
Repurchases of common stock		-1,531
Net (payments) proceeds from the issuance of common stock (sale of stock under ESPP and exercise of stock options)	-965	1,018
Payment of cash dividends	-569	-1,418
Net cash (used in) provided by financing activities	-16,084	45,398
Net increase in cash and cash equivalents	2,236	1,692
Cash and cash equivalents at beginning of period	4,885	6,680
Effect of exchange rate changes on cash	-251	19
Cash and cash equivalents at end of period	$6,870	$8,391

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Summary of Significant Accounting Policies	1. The accompanying unaudited condensed consolidated financial statements of American Vanguard Corporation and Subsidiaries (“AVD”) have been prepared in accordance with generally accepted accounting principles in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation, have been included. Operating results for the three months ended March 31, 2015 are not necessarily indicative of the results that may be expected for the year ending December 31, 2015. For further information, refer to the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014.

Property_plant_and_equipment

Property, plant and equipment	3 Months Ended
	Mar. 31, 2015
Property, plant and equipment	2. Property, plant and equipment at March 31, 2015 and December 31, 2014 consists of the following:
		March 31,			December 31,
		2015			2014
	Land	$	2,458		$	2,458
	Buildings and improvements		14,385			14,380
	Machinery and equipment		108,286			107,899
	Office furniture, fixtures and equipment		4,542			4,698
	Automotive equipment		374			374
	Construction in progress		4,548			3,432
			134,593			133,241
	Less accumulated depreciation		(85,406	)		(83,215	)
		$	49,187		$	50,026
	During the three months ended March 31, 2015, the Company eliminated from assets and accumulated depreciation $136 of fully depreciated assets.
	Substantially all of the Company’s assets are pledged as collateral with its banks.

Inventories

Inventories	3 Months Ended
	Mar. 31, 2015
Inventories	3. Inventories are stated at the lower of cost or market. Cost is determined using the first-in, first-out method. The components of inventories consist of the following:
		March 31,		December 31,
		2015		2014
	Finished products	$	142,269	$	142,853
	Raw materials		24,712		22,778
		$	166,981	$	165,631

Segment_Reporting

Segment Reporting	3 Months Ended
	Mar. 31, 2015
Segment Reporting	4. Based on similar economic and operational characteristics, the Company’s business is aggregated into one reportable segment. Selective enterprise information is as follows:
		Three Months Ended
		March 31
		2015		2014
	Net sales:
	Insecticides	$	34,359	$	46,437
	Herbicides/soil fumigants/fungicides		21,840		22,931
	Other, including plant growth regulators		3,322		3,807
			59,521		73,175
	Non-crop		7,044		7,920
		$	66,565	$	81,095
		Three Months Ended
		March 31
		2015		2014
	Net sales:
	US	$	49,222	$	57,956
	International		17,343		23,139
		$	66,565	$	81,095

Accrued_Program_Costs

Accrued Program Costs	3 Months Ended
	Mar. 31, 2015
Accrued Program Costs	5. Accrued Program Costs - In accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 605, the Company classifies certain payments to its customers as a reduction of sales revenues. The Company describes these payments as “Programs.” Programs are a critical part of doing business in the agricultural chemicals business market place. For accounting purposes, programs are recorded as a reduction in gross sales and include market pricing adjustments, volume take up or other key performance indicators, driven payments made to distributors, retailers or growers at the end of a growing season. Each quarter management compares each sale transaction with published programs to determine what program liability has been incurred. Once this initial calculation is made for the specific quarter, sales and marketing management along with executive and financial management review the accumulated program balance and make assessments of whether or not customers are tracking in a manner that indicates that they will meet the requirements set out in the terms and conditions attached to each program. If management believes that customers are falling short of or exceeding their annual goals then periodic adjustments will be made to the accumulated accrual to properly reflect the Company’s best estimate of the liability at the balance sheet date. The majority of adjustments are made at the end of the crop season, at which time customer performance can be fully assessed. Programs are paid out predominantly on an annual basis, usually in the final quarter of the financial year or the first quarter of the following year.

Cash_Dividends

Cash Dividends	3 Months Ended
	Mar. 31, 2015
Cash Dividends	6. The Company has declared the following cash dividend in the period covered by this Form 10-Q:
	Declaration Date	Distribution Date	Record Date	Dividend	Total
				Per Share	Paid
	March 16, 2015	17-Apr-15	3-Apr-15	$0.02	$572

Earnings_Per_Share

Earnings Per Share	3 Months Ended
	Mar. 31, 2015
Earnings Per Share	7. ASC 260 Earnings Per Share (“EPS”) requires dual presentation of basic EPS and diluted EPS on the face of our condensed consolidated statements of operations and comprehensive (loss) income. Basic EPS is computed as net income divided by the weighted average number of shares of common stock outstanding during the period. Diluted EPS reflects potential dilution that could occur if securities or other contracts, which, for the Company, consists of options to purchase shares of the Company’s common stock, are exercised.
	The components of basic and diluted earnings per share were as follows:
		Three Months Ended
		March 31,
		2015		2014
	Numerator:
	Net income attributable to AVD	$	51	$	2,159
	Denominator:
	Weighted averages shares outstanding-basic		28,527		28,401
	Dilutive effect of stock options and grants		312		487
			28,839		28,888
	The Company has excluded options to acquire 276,654 shares from fully diluted earnings per share for the three months ended March 31, 2015 because to include those options would be anti-dilutive. For the three months ended March 31, 2014, no stock options were excluded from the computation.

Indebtedness

Indebtedness	3 Months Ended
	Mar. 31, 2015
Indebtedness	8. The Company has a revolving line of credit and various notes payable that together constitute the short-term and long-term loan balances shown in the condensed consolidated balance sheets at March 31, 2015 and December 31, 2014. These are summarized in the following table:
	Indebtedness	March 31, 2015							December 31, 2014
	$000’s	Long-		Short-			Total		Long-		Short-			Total
		term		term					term		term
	Revolving line of credit	$	85,000	$	—		$	85,000	$	99,400	$	—		$	99,400
	Notes payable		36		272			308		55		71			126
	Total indebtedness	$	85,036	$	272		$	85,308	$	99,455	$	71		$	99,526
	On June 17, 2013, AMVAC Chemical Corporation (“AMVAC”), the Company’s principal operating subsidiary, as borrower, and affiliates (including the Company), as guarantors and/or borrowers, entered into a Second Amended and Restated Credit Agreement (the “New Credit Agreement”) with a group of commercial lenders led by Bank of the West (AMVAC’s primary bank) as agent, swing line lender and L/C issuer. The new facility also includes both AMVAC C.V. and AMVAC Netherlands BV (both Dutch subsidiaries) as borrowers. The New Credit Agreement supersedes the Amended and Restated Credit Agreement (“First Amendment”) dated as of January 10, 2011. The New Credit Agreement is a senior secured lending facility with a five year term and consists of a revolving line of credit with a maximum limit of $200 million and an accordion feature with a maximum limit of $100 million. The actual borrowing capacity under this facility depends upon its compliance with the key covenants described below. In connection with AMVAC’s entering into the New Credit Agreement, all outstanding indebtedness under the First Amendment was rolled over into the New Credit Agreement, including the conversion of term loans into revolving debt.
	The Company has three key covenants to its senior, secured credit facility with its banking syndicate. The covenants are as follows: (1) the Company must maintain its borrowings below a certain consolidated funded debt ratio (taking into account the Company’s twelve month trailing EBITDA), (2) the Company has a limitation on its annual spending on the acquisition of fixed asset capital additions, and (3) the Company must maintain a certain consolidated fixed charge coverage ratio. As of March 31, 2015 the Company met all covenants in that credit facility.
	At March 31, 2015, based on its performance against the most restrictive covenants listed above, the Company had the capacity to increase its borrowings by up to $22,710 under the credit facility agreement. This compares to an available borrowing capacity of $87,814 as of March 31, 2014. This decrease in borrowing availability arises from reduced financial performance (as measured in EBITDA) for the trailing twelve month period.
	On July 18, 2014, AMVAC, as borrower, and affiliates (including the Company), as guarantors and/or borrowers, entered into a First Amendment to Second Amended and Restated Credit Agreement (the “First Amendment”) with a group of commercial lenders led by Bank of the West (AMVAC’s primary bank) as agent, swing line lender and L/C issuer. Under the First Amendment, the Consolidated Funded Debt Ratio was increased for the third and fourth quarters of 2014 and the first quarter of 2015, and, further, borrowers are permitted to pay cash dividends to stockholders during the first and second quarters of 2015 notwithstanding prior net income levels.
	During the three month period ended March 31, 2014 (and throughout the balance of 2014, terminating on December 31, 2014), the Company had in place one interest rate swap contract. While in place, the interest rate swap contract was accounted for under FASB ASC 815 as a cash flow hedge. The effective portion of the gains or losses on the interest rate swap were reported as a component of other comprehensive income and reclassified into earnings in the same period or periods during which the hedged transactions affected earnings. As a result of the termination of the swap contract, there are no gains or losses in other comprehensive income related to interest rate swap contracts that are expected to be reclassified to earnings in the coming 12 months.
	The following tables illustrate the impact of derivatives on the Company’s statement of operations for the quarter ended March 31, 2015 and the quarter ended March 31, 2014.
	The Effect of Derivative Instruments on the Statement of Financial Performance
	For the Period Ended March 31
		Amount of Gain or					Location of Gain or		Amount of Gain or (Loss)					Location of Gain or		Amount of Gain or
		(Loss) Recognized in					(Loss) Reclassified		Reclassified from Accumulated					(Loss) Recognized in		(Loss)
		OCI on Derivative					from Accumulated		OCI into Income  (Effective							Recognized
		(Effective Portion)							Portion)							in Income on
																Derivative
																(Ineffective  Portion)
	Derivatives in ASC 815 Cash Flow	2015		2014			OCI into Income		2015		2014			Income on Derivative		2015		2014
	Hedging Relationships						(Effective Portion)							(Ineffective Portion)
	Interest rate contracts	$	—	$	(23	)		InterestExpense	$	—	$	(159	)		Interest Expense	$	—	$	—
	Total	$	—	$	(23	)			$	—	$	(159	)			$	—	$	—

Reclassification

Reclassification	3 Months Ended
	Mar. 31, 2015
Reclassification	9. Reclassification—Certain items may have been reclassified in the prior period condensed consolidated financial statements to conform with the March 31, 2015 presentation.

Comprehensive_Loss_Income

Comprehensive (Loss) Income	3 Months Ended
	Mar. 31, 2015
Comprehensive (Loss) Income	10. Total comprehensive (loss) income includes, in addition to net income, changes in equity that are excluded from the condensed consolidated statements of operations and are recorded directly into a separate section of stockholders’ equity on the condensed consolidated balance sheets. For the three month period ended March 31, 2015, total comprehensive income consisted of net income attributable to American Vanguard and foreign currency translation adjustments.

Stock_Based_Compensation_Expen

Stock Based Compensation Expense	3 Months Ended
	Mar. 31, 2015
Stock Based Compensation Expense	11. Stock Based Compensation Expense—The Company accounts for stock-based awards to employees and directors in accordance with FASB ASC 718, “Share-Based Payment,” which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and directors including shares of common stock granted for services, employee stock options, and employee stock purchases related to the Employee Stock Purchase Plan (“employee stock purchases”) based on estimated fair values.
	Stock Options—During the three months ended March 31, 2015, the Company did not grant any employees options to acquire shares of common stock.
	Option activity within each plan is as follows:
		Incentive			Weighted Average		Exercisable
		Stock Option			Price Per Share		Weighted
		Plans					Average
							Price
							Per Share
	Balance outstanding, December 31, 2014		724,904		$	9.22	$	7.82
	Options exercised, $7.50		(16,650	)		7.5
	Options forfeited, $11.49 and $13.24		(10,400	)		11.49
	Balance outstanding, March 31, 2015		697,854		$	9.21	$	7.71
	Information relating to stock options at March 31, 2015 summarized by exercise price is as follows:
		Outstanding Weighted Average							Exercisable Weighted
									Average
	Exercise Price Per Share	Shares			Remaining		Exercise		Shares		Exercise
					Life		Price				Price
					(Months)
	Incentive Stock Option Plan:
	$7.50		404,550			68	$	7.5		404,550	$	7.5
	$11.32—$14.75		293,304			114	$	11.56		16,679	$	12.69
			697,854				$	9.21		421,229	$	7.71
	The weighted average exercise prices for options granted and exercisable and the weighted average remaining contractual life for options outstanding as of March 31, 2015 were as follows:
		Number			Weighted		Weighted		Intrinsic
		of			Average		Average		Value
		Shares			Exercise		Remaining		(thousands)
					Price		Contractual
							Life
							(Months)
	As of March 31, 2015:
	Incentive Stock Option Plans:
	Outstanding		697,854		$	9.21		87	$	1,262
	Expected to Vest		686,973		$	9.17		89	$	1,262
	Exercisable		421,229		$	7.71		71	$	1,262
	As of March 31, 2015, the intrinsic value of $1,262 is calculated based on the Company’s publicly traded closing price of $10.62 per share as compared to the specific exercise price of each option. At March 31, 2015, 404,550 incentive stock options were outstanding, expected to vest and exercisable and have an exercise price below the closing market price. Incentive stock options in each category in excess of 404,550 (293,304 of outstanding options, 282,423 of those options expected to vest and 16,679 of those options that are exercisable at March 31, 2015) had exercise price above $10.62 and were therefore excluded from the intrinsic value computation.
	During the three months ended March 31, 2015 and 2014, the Company recognized stock-based compensation expense, excluding expense related to modifications, related to stock options of $115 and $11, respectively.
	As of March 31, 2015, the Company had approximately $1,336 of unamortized stock-based compensation expenses related to unvested stock options outstanding. This amount will be recognized over the weighted-average period of 2.7 years. This projected expense will change if any stock options are granted or cancelled prior to the respective reporting periods or if there are any changes required to be made for estimated forfeitures.
	Restricted Shares — A summary of non-vested shares as of and for the three months ended March 31, 2015 is presented below:
		Number			Weighted
		of			Average
		Shares			Grant-
					Date
					Fair Value
	Nonvested shares at December 31, 2014		560,842		$	21.44
	Granted		30,000			11.42
	Vested		(192,266	)		20.47
	Forfeited		(422	)		14.92
	Nonvested shares at March 31, 2015		398,154		$	21.17
	Restricted Shares — During the three months ended March 31, 2015, the Company granted a total of 30,000 shares of common stock. Of these, 7,500 shares will vest after 90 days and the balance will vest one-third each year on the anniversaries of the employee’s employment date. The shares granted in 2015 were average fair valued at $11.42 per share. The fair value was determined by using the publicly traded share price as of the date of grant. The Company is recognizing as expense the value of restricted shares over the required service period of three years. During the three months ended March 31, 2015, there were 422 restricted shares that forfeited, which had an average grant-date value of $14.92 per share.
	During the three months ended March 31, 2014, the Company did not grant any shares of restricted common stock.
	During the three months ended March 31, 2015 and 2014, the Company recognized stock-based compensation expense related to restricted shares of $1,172 and $834, respectively.
	As of March 31, 2015, the Company had approximately $4,010 of unamortized stock-based compensation expense related to unvested restricted shares. This amount will be recognized over the weighted-average period of 1.3 years. This projected expense will change if any restricted shares are granted or cancelled prior to the respective reporting periods or if there are any changes required to be made for estimated forfeitures.
	Performance Based Shares—A summary of non-vested performance based shares as of and for the three months ended March 31, 2015 is presented below:
		Number			Weighted
		of			Average
		Shares			Grant-
					Date
					Fair Value
	Nonvested shares at December 31, 2014		103,907		$	17.81
	Granted		7,500			10.96
	Vested		—			—
	Forfeited		—			—
	Nonvested shares at March 31, 2015		111,407		$	17.35
	Performance Based Shares — During the three months ended March 31, 2015, the Company granted a total of 7,500 performance based shares that will cliff vest on January 5, 2018, provided that the recipient is continuously employed by the Company during the vesting period. Eighty percent of these performance based shares are based upon financial performance of the Company, specifically, an earnings before income tax (“EBIT”) goal weighted at 50% and a net sales goal weighted at 30% for the period commencing January 1, 2015 and ending December 31, 2017. The remaining 20% of performance based shares are based upon AVD stock price appreciation over the same performance measurement period. The EBIT and net sales goal measures the relative growth of the Company’s EBIT and net sales for the performance measurement period, as compared to the median growth of EBIT and net sales for an identified peer group. The stockholder return goal measures the relative growth of the fair market value of the Company’s stock price over the performance measurement period, as compared to that of the Russell 2000 Index and the median fair market value of the common stock of the comparator companies, identified in the Company’s 2015 Proxy Statement. All parts of these awards vest in three years, but are subject to reduction to a minimum (or even zero) for meeting less than the targeted performance and to increase to a maximum of 200% for meeting in excess of the targeted performance. The Company did not grant any performance based shares during the comparable period last year.
As of March 31, 2015, performance based shares related to net income and net sales have an average fair value of $11.42 per share. The fair value was determined by using the publicly traded share price as of the date of grant. The performance based shares related to the Company’s stock price have an average fair value of $9.13 per share. The fair value was determined by using the Monte Carlo valuation method. For awards with performance conditions, the Company recognizes share-based compensation cost on a straight-line basis for each performance criteria over the implied service period when the Company believes it is probable that the performance targets, as defined in the agreements, will be achieved.
During the three months ended March 31, 2015, the Company recognized stock-based compensation expense related to performance based shares of $98. During the three months ended March 31, 2014, the Company recognized a reduction in stock-based compensation expense related to performance based shares of $77.
As of March 31, 2015, the Company had approximately $917 of unamortized stock-based compensation expense related to unvested performance based shares. This amount will be recognized over the weighted-average period of 1.9 years. This projected expense will change if any performance based shares are granted or cancelled prior to the respective reporting periods or if there are any changes required to be made for estimated forfeitures.
Performance Incentive Stock Options—During the three months ended March 31, 2015 and 2014, the Company did not grant any employees performance incentive stock options to acquire shares of common stock.
Performance option activity is as follows:
	Incentive			Weighted Average		Exercisable
	Stock Option			Price Per Share		Weighted
	Plans					Average
						Price
						Per Share
Balance outstanding, December 31, 2014		107,689		$	11.49	$	—
Balance outstanding, March 31, 2015		107,689		$	11.49	$	—
Information relating to stock options at March 31, 2015 summarized by exercise price is as follows:
	Outstanding Weighted Average							Exercisable Weighted
								Average
Exercise Price Per Share	Shares			Remaining		Exercise		Shares		Exercise
				Life		Price				Price
				(Months)
Performance Incentive Stock Option Plan:
$11.49		107,689			33	$	11.49		—	$	—
		107,689				$	11.49		—	$	—
The weighted average exercise prices for options granted and exercisable and the weighted average remaining contractual life for options outstanding as of March 31, 2015 are as follows:
	Number			Weighted		Weighted		Intrinsic
	of			Average		Average		Value
	Shares			Exercise		Remaining		(thousands)
				Price		Contractual
						Life
						(Months)
As of March 31, 2015:
Incentive Stock Option Plans:
Outstanding		107,689		$	11.49		33	$	—
Expected to Vest		107,689		$	11.49		33	$	—
Exercisable		—		$	—		—	$	—
During the three months ended March 31, 2015 the Company recognized stock-based compensation expense, excluding expense related to modifications, related to performance stock options of $42. There were no performance incentive stock options issued by the Company prior to those issued during the quarter ended December 31, 2014.
As of March 31, 2015, the Company had approximately $499 of unamortized stock-based compensation expenses related to unvested performance incentive stock options outstanding. This amount will be recognized over the weighted-average period of 2.8 years. This projected expense will change if any performance incentive stock options are granted or cancelled prior to the respective reporting periods or if there are any changes required to be made for estimated forfeitures.

Legal_Proceedings

Legal Proceedings	3 Months Ended
	Mar. 31, 2015
Legal Proceedings	12. Legal Proceedings— During the reporting period, there have been no material developments in legal matters that were reported in the Company’s Form 10-K for the period ended December 31, 2014. One new matter has arisen during the reporting period:
	On or about March 24, 2015, Region 4 of the United States Environmental Protection Agency (USEPA) issued to registrant’s principal operating subsidiary (AMVAC Chemical Corporation) an Opportunity to Show Cause why USEPA should not take formal action under Section 3008(a) of the Resource Conservation and Recovery Act (RCRA) for potential noncompliance arising from AMVAC’s importation, transportation and storage of used, depleted Lock‘N Load containers having residual amounts of its product Thimet. AMVAC believes that these containers were properly handled and stored under, among others, the applicable provisions of the Federal Insecticide, Fungicide and Rodenticide Act relating to recycling and disposal of depleted, refillable containers (and their contents). AMVAC responded to the substance of the Show Cause letter on April 10, 2015 and requested a meeting on the matter. While violations of RCRA, if any, may carry civil penalties, it is too early in the matter to determine whether a loss is probable or reasonably estimable. Accordingly, the Company has not set up a loss contingency on this matter.

Recently_Issued_Accounting_Gui

Recently Issued Accounting Guidance	3 Months Ended
	Mar. 31, 2015
Recently Issued Accounting Guidance	13. Recently Issued Accounting Guidance— In April 2015, The Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2015-03, Interest – Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. This ASU requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by the amendments in this update. ASU 2015-03 is effective for financials statement issued for fiscal years beginning after December 15, 2015. The Company is evaluating the impact of this update and will adopt this update.
	In August 2014, FASB issued ASU 2014-15, Presentation of Financial Statements – Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. This ASU requires that management of an entity assesses whether there is substantial doubt about the ability of the entity to continue as a going concern and for making the appropriate disclosures. The assessment must be performed at each annual and interim reporting period, and there is substantial doubt about an entity’s ability to continue as a going concern if it is probable that the entity will be unable to meet its obligations as they become due within 12 months of the date of the financial statements are issued. In the assessment, management must consider the information available at the date of issuance of the financial statements, as well as mitigating factors and plans to alleviate the substantial doubt. ASU 2014-15 is effective for annual period ending after December 15, 2016 and interim periods thereafter. Early application is permitted. Upon adoption, the Company will follow the guidance in this ASU when assessing going concern.
	In June 2014, FASB issued ASU 2014-12, Compensation—Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period, a consensus of the FASB Emerging Issues Task Force. ASU 2014-12 requires that a performance target that affects vesting of share-based payment awards and that could be achieved after the requisite service period be treated as a performance condition. Compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the periods for which the requisite service has already been rendered. If the performance target becomes probable of being achieved before the end of the requisite service period, the remaining unrecognized compensation cost should be recognized prospectively over the remaining requisite service period. The total amount of compensation cost recognized during and after the requisite service period should reflect the number of awards that are expected to vest and should be adjusted to reflect those awards that ultimately vest. The requisite service period ends when the employee can cease rendering service and still be eligible to vest in the award if the performance target is achieved. ASU 2014-12 is effective for all entities for interim and annual periods beginning after December 15, 2015, with early adoption permitted. An entity may apply the amendments in ASU 2014-12 either (i) prospectively to all awards granted or modified after the effective date or (ii) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. The adoption of ASU 2014-12 is not expected to have a material impact on the Company’s consolidated financial condition or results of operations.
	In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers. ASU 2014-09 outlines a new, single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. This new revenue recognition model provides a five-step analysis in determining when and how revenue is recognized. The new model will require revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration a company expects to receive in exchange for those goods or services. The standard is effective for annual periods beginning after December 15, 2016, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). We are currently evaluating the impact of our pending adoption of ASU 2014-09 on our consolidated financial statements and have not yet determined the method by which we will adopt the standard in 2017 or its impact on our consolidated financial statements.

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2015
Fair Value of Financial Instruments	14. Fair Value of Financial Instruments—The carrying values of cash, receivables and accounts payable approximate their fair values because of the short maturity of these instruments. The fair value of the Company’s long-term debt and note payable to bank is estimated based on the quoted market prices for the same or similar issues or on the current rates offered to the Company for debt of the same remaining maturities. Such fair value approximates the respective carrying values of the Company’s long-term debt and note payable to bank.

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Income ("AOCI")	3 Months Ended
	Mar. 31, 2015
Accumulated Other Comprehensive Income ("AOCI")	15. Accumulated Other Comprehensive Income (“AOCI”)-
	The following table lists the beginning balance, annual activity and ending balance of accumulated other comprehensive loss, which consists of foreign currency translation adjustments:
	Balance, December 31, 2014	$	(1,970	)
	Other comprehensive loss		(248	)
	Balance, March 31, 2015	$	(2,218	)

Equity_Investment

Equity Investment	3 Months Ended
	Mar. 31, 2015
Equity Investment	16. On March 25, 2013, the Company made a $3,687 equity investment in TyraTech Inc. (“TyraTech”), a Delaware corporation that specializes in developing, marketing and selling pesticide products containing essential oils and other natural ingredients, to acquire an ownership position of approximately 29.27%. In February 2014, TyraTech issued 37,391,763 shares and raised approximately £1,870 ($3,100). Due to the share issuance, the Company recognized a $256 gain from the dilution of the Company’s ownership position. As of March 31, 2015, the Company’s ownership position in TyraTech was approximately 21.18%. The Company utilizes the equity method of accounting with respect to this investment. As a result, our net income includes losses from equity method investments, which represents our proportionate share of TyraTech’s estimated net losses for the current accounting period. For the three months ended March 31, 2015, the Company recognized no gain or loss as a result of the Company’s ownership position in TyraTech.
	The Company’s investment in TyraTech is included in other assets on the condensed consolidated balance sheet. At March 31, 2015, the carrying value of the Company’s investment in TyraTech was $3,172 and the quoted market value of its shareholding was $3,914 based on the London Stock Exchange, Alternative Investment Market (“AIM”).

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2015
Income Taxes	17. Income Taxes – Income tax benefit was $292 for the three months ended March 31, 2015 as compared to an income tax expense of $1,016 for the three months ended March 31, 2014. The effective tax rate was 87.2% in 2015 and 30.0% in 2014.
	The effective tax rate for the three months ended March 31, 2015 is based on the projected income for the full year and is subject to ongoing review and adjustment by management.

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2015
Subsequent Events	18. Subsequent Events – On April 1, 2015, the Company entered into an agreement with TyraTech to change our ownership in Envance Technologies, LLC from 60% to 87%.
	On April 2, 2015, the Company’s international subsidiary, AMVAC C.V., through its wholly owned subsidiary, AMVAC Netherlands B.V., acquired the Nemacur nematicide product line in Europe (“E.U.”) from Adama Agricultural Solutions Ltd. Nemacur is a highly effective insecticide/nematicide used to control soil insects and nematodes on many fruit and vegetable crops. The assets acquired in this transaction include trademarks, product registrations, associated registration data and customer information related to the marketing, distribution and sale of Nemacur in the E.U.
	On April 29, 2015 the Company’s international subsidiary, AMVAC C.V. completed the product line acquisition of Bromacil from E.I. du Pont de Nemours and Company for territories outside of the U.S. and Canada. Bromacil is a broad spectrum residual herbicide used on crops such as pineapples, citrus, agave, and asparagus. Bromacil is also used to control many annual weeds at lower rates and perennial weeds and brush at the highest rates permitted by the label. It is particularly useful for the control of perennial grasses. The assets acquired in this transaction include trademarks, product registrations, associated registration data and customer information related to the marketing, distribution and sale of Bromacil.
	With the completion of the Bromacil purchase on April 28, 2015 the Company’s principal operating subsidiary, AMVAC Chemical Corporation (“AMVAC”), as borrower, and affiliates (including the Company), as guarantors and/or borrowers, entered into a Second Amendment to the Second Amended and Restated Credit Agreement (the “Second Amendment”) with a group of commercial lenders led by Bank of the West (AMVAC’s primary bank) as agent, swing line lender and L/C issuer. The details of the amendment include an increase in the leverage covenant ratio for the last three quarters of 2015. Further, a new covenant involving the coverage of fixed charges (in effect, the ratio of consolidated current assets to consolidated current liabilities) was added to the credit facility for the duration of its term.

Property_plant_and_equipment_T

Property, plant and equipment (Tables)	3 Months Ended
	Mar. 31, 2015
Summary of Property, Plant and Equipment	Property, plant and equipment at March 31, 2015 and December 31, 2014 consists of the following:
		March 31,			December 31,
		2015			2014
	Land	$	2,458		$	2,458
	Buildings and improvements		14,385			14,380
	Machinery and equipment		108,286			107,899
	Office furniture, fixtures and equipment		4,542			4,698
	Automotive equipment		374			374
	Construction in progress		4,548			3,432
			134,593			133,241
	Less accumulated depreciation		(85,406	)		(83,215	)
		$	49,187		$	50,026

Inventories_Tables

Inventories (Tables)	3 Months Ended
	Mar. 31, 2015
Components of Inventories	The components of inventories consist of the following:
		March 31,		December 31,
		2015		2014
	Finished products	$	142,269	$	142,853
	Raw materials		24,712		22,778
		$	166,981	$	165,631

Segment_Reporting_Tables

Segment Reporting (Tables)	3 Months Ended
	Mar. 31, 2015
Summary of Business Sales Segmentation as per Product	Selective enterprise information is as follows:
		Three Months Ended
		March 31
		2015		2014
	Net sales:
	Insecticides	$	34,359	$	46,437
	Herbicides/soil fumigants/fungicides		21,840		22,931
	Other, including plant growth regulators		3,322		3,807
			59,521		73,175
	Non-crop		7,044		7,920
		$	66,565	$	81,095
Summary of Business Sales Segmentation as per Location
		Three Months Ended
		March 31
		2015		2014
	Net sales:
	US	$	49,222	$	57,956
	International		17,343		23,139
		$	66,565	$	81,095

Cash_Dividends_Tables

Cash Dividends (Tables)	3 Months Ended
	Mar. 31, 2015
Cash Dividends	The Company has declared the following cash dividend in the period covered by this Form 10-Q:
	Declaration Date	Distribution Date	Record Date	Dividend	Total
				Per Share	Paid
	March 16, 2015	17-Apr-15	3-Apr-15	$0.02	$572

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	3 Months Ended
	Mar. 31, 2015
Components of Basic and Diluted Earnings Per Share	The components of basic and diluted earnings per share were as follows:
		Three Months Ended
		March 31,
		2015		2014
	Numerator:
	Net income attributable to AVD	$	51	$	2,159
	Denominator:
	Weighted averages shares outstanding-basic		28,527		28,401
	Dilutive effect of stock options and grants		312		487
			28,839		28,888

Indebtedness_Tables

Indebtedness (Tables)	3 Months Ended
	Mar. 31, 2015
Summary of Short-Term and Long-Term Loan Balances in Condensed Consolidated Balance Sheets	The Company has a revolving line of credit and various notes payable that together constitute the short-term and long-term loan balances shown in the condensed consolidated balance sheets at March 31, 2015 and December 31, 2014. These are summarized in the following table:
	Indebtedness	March 31, 2015							December 31, 2014
	$000’s	Long-		Short-			Total		Long-		Short-			Total
		term		term					term		term
	Revolving line of credit	$	85,000	$	—		$	85,000	$	99,400	$	—		$	99,400
	Notes payable		36		272			308		55		71			126
	Total indebtedness	$	85,036	$	272		$	85,308	$	99,455	$	71		$	99,526
Summary of Effect of Derivative Instruments on Statement of Operations	The following tables illustrate the impact of derivatives on the Company’s statement of operations for the quarter ended March 31, 2015 and the quarter ended March 31, 2014.
	The Effect of Derivative Instruments on the Statement of Financial Performance
	For the Period Ended March 31
		Amount of Gain or					Location of Gain or		Amount of Gain or (Loss)					Location of Gain or		Amount of Gain or
		(Loss) Recognized in					(Loss) Reclassified		Reclassified from Accumulated					(Loss) Recognized in		(Loss)
		OCI on Derivative					from Accumulated		OCI into Income  (Effective							Recognized
		(Effective Portion)							Portion)							in Income on
																Derivative
																(Ineffective  Portion)
	Derivatives in ASC 815 Cash Flow	2015		2014			OCI into Income		2015		2014			Income on Derivative		2015		2014
	Hedging Relationships						(Effective Portion)							(Ineffective Portion)
	Interest rate contracts	$	—	$	(23	)		InterestExpense	$	—	$	(159	)		Interest Expense	$	—	$	—
	Total	$	—	$	(23	)			$	—	$	(159	)			$	—	$	—

Stock_Based_Compensation_Expen1

Stock Based Compensation Expense (Tables)	3 Months Ended
	Mar. 31, 2015
Summary of Option Activity	Option activity within each plan is as follows:
		Incentive			Weighted Average		Exercisable
		Stock Option			Price Per Share		Weighted
		Plans					Average
							Price
							Per Share
	Balance outstanding, December 31, 2014		724,904		$	9.22	$	7.82
	Options exercised, $7.50		(16,650	)		7.5
	Options forfeited, $11.49 and $13.24		(10,400	)		11.49
	Balance outstanding, March 31, 2015		697,854		$	9.21	$	7.71
Summary of Stock Options Summarized by Exercise Price	Information relating to stock options at March 31, 2015 summarized by exercise price is as follows:
		Outstanding Weighted Average							Exercisable Weighted
									Average
	Exercise Price Per Share	Shares			Remaining		Exercise		Shares		Exercise
					Life		Price				Price
					(Months)
	Incentive Stock Option Plan:
	$7.50		404,550			68	$	7.5		404,550	$	7.5
	$11.32—$14.75		293,304			114	$	11.56		16,679	$	12.69
			697,854				$	9.21		421,229	$	7.71
Weighted Average Exercise Prices for Options Granted and Exercisable and Weighted Average Remaining Contractual Life for Options Outstanding	The weighted average exercise prices for options granted and exercisable and the weighted average remaining contractual life for options outstanding as of March 31, 2015 were as follows:
		Number			Weighted		Weighted		Intrinsic
		of			Average		Average		Value
		Shares			Exercise		Remaining		(thousands)
					Price		Contractual
							Life
							(Months)
	As of March 31, 2015:
	Incentive Stock Option Plans:
	Outstanding		697,854		$	9.21		87	$	1,262
	Expected to Vest		686,973		$	9.17		89	$	1,262
	Exercisable		421,229		$	7.71		71	$	1,262
Performance Incentive Stock Option Plan
Summary of Option Activity	Performance option activity is as follows:
		Incentive			Weighted Average		Exercisable
		Stock Option			Price Per Share		Weighted
		Plans					Average
							Price
							Per Share
	Balance outstanding, December 31, 2014		107,689		$	11.49	$	—
	Balance outstanding, March 31, 2015		107,689		$	11.49	$	—
Summary of Stock Options Summarized by Exercise Price	Information relating to stock options at March 31, 2015 summarized by exercise price is as follows:
		Outstanding Weighted Average							Exercisable Weighted
									Average
	Exercise Price Per Share	Shares			Remaining		Exercise		Shares		Exercise
					Life		Price				Price
					(Months)
	Performance Incentive Stock Option Plan:
	$11.49		107,689			33	$	11.49		—	$	—
			107,689				$	11.49		—	$	—
Weighted Average Exercise Prices for Options Granted and Exercisable and Weighted Average Remaining Contractual Life for Options Outstanding	The weighted average exercise prices for options granted and exercisable and the weighted average remaining contractual life for options outstanding as of March 31, 2015 are as follows:
		Number			Weighted		Weighted		Intrinsic
		of			Average		Average		Value
		Shares			Exercise		Remaining		(thousands)
					Price		Contractual
							Life
							(Months)
	As of March 31, 2015:
	Incentive Stock Option Plans:
	Outstanding		107,689		$	11.49		33	$	—
	Expected to Vest		107,689		$	11.49		33	$	—
	Exercisable		—		$	—		—	$	—
Restricted Stock
Summary of Non-Vested Shares	Restricted Shares— A summary of non-vested shares as of and for the three months ended March 31, 2015 is presented below:
		Number			Weighted
		of			Average
		Shares			Grant-
					Date
					Fair Value
	Nonvested shares at December 31, 2014		560,842		$	21.44
	Granted		30,000			11.42
	Vested		(192,266	)		20.47
	Forfeited		(422	)		14.92
	Nonvested shares at March 31, 2015		398,154		$	21.17
Performance Shares
Summary of Non-Vested Shares	Performance Based Shares—A summary of non-vested performance based shares as of and for the three months ended March 31, 2015 is presented below:
		Number			Weighted
		of			Average
		Shares			Grant-
					Date
					Fair Value
	Nonvested shares at December 31, 2014		103,907		$	17.81
	Granted		7,500			10.96
	Vested		—			—
	Forfeited		—			—
	Nonvested shares at March 31, 2015		111,407		$	17.35

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Income ("AOCI") (Tables)	3 Months Ended
	Mar. 31, 2015
Beginning Balance, Annual Activity and Ending Balance of Accumulated Other Comprehensive Loss of of Foreign Currency Translation Adjustments	The following table lists the beginning balance, annual activity and ending balance of accumulated other comprehensive loss, which consists of foreign currency translation adjustments:
	Balance, December 31, 2014	$	(1,970	)
	Other comprehensive loss		(248	)
	Balance, March 31, 2015	$	(2,218	)

Summary_of_Property_Plant_and_

Summary of Property, Plant and Equipment (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]
Property, plant and equipment, Gross	$134,593	$133,241
Less accumulated depreciation	-85,406	-83,215
Total Property, plant and equipment	49,187	50,026
Land
Property, Plant and Equipment [Line Items]
Property, plant and equipment, Gross	2,458	2,458
Buildings and improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, Gross	14,385	14,380
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, Gross	108,286	107,899
Office furniture, fixtures and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, Gross	4,542	4,698
Automotive equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, Gross	374	374
Construction in progress
Property, Plant and Equipment [Line Items]
Property, plant and equipment, Gross	$4,548	$3,432

Property_Plant_and_Equipment_A

Property, Plant and Equipment - Additional Information (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015
Property, Plant and Equipment [Line Items]
Elimination of Assets and Accumulated depreciation	$136

Components_of_Inventories_Deta

Components of Inventories (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Inventory [Line Items]
Finished products	$142,269	$142,853
Raw materials	24,712	22,778
Total Inventories	$166,981	$165,631

Segment_Reporting_Additional_I

Segment Reporting - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2015
	Segment
Number of reportable business segments	1

Summary_of_Business_Sales_Segm

Summary of Business Sales Segmentation as per Product (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Net Sales:
Total crop	$59,521	$73,175
Non-crop	7,044	7,920
Net sales	66,565	81,095
Insecticides
Net Sales:
Total crop	34,359	46,437
Herbicides/Soil Fumigants/Fungicides
Net Sales:
Total crop	21,840	22,931
Other, Including Plant Growth Regulators
Net Sales:
Total crop	$3,322	$3,807

Summary_of_Business_Sales_Segm1

Summary of Business Sales Segmentation as per Location (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Net Sales:
Net sales	$66,565	$81,095
US
Net Sales:
Net sales	49,222	57,956
International
Net Sales:
Net sales	$17,343	$23,139

Cash_Dividends_Detail

Cash Dividends (Detail) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015
Dividends [Line Items]
Cash dividend declaration date	16-Mar-15
Cash dividend distributed date	17-Apr-15
Cash dividend record date	3-Apr-15
Cash dividend per share	$0.02
Cash dividends paid	$572

Components_of_Basic_and_Dilute

Components of Basic and Diluted Earnings Per Share (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Numerator:
Net income attributable to AVD	$51	$2,159
Denominator:
Weighted averages shares outstanding-basic	28,527	28,401
Dilutive effect of stock options and grants	312	487
Weighted average shares outstanding-assuming dilution	28,839	28,888

Earnings_Per_Share_Additional_

Earnings Per Share - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Components Of Basic And Diluted Earning Per Share [Line Items]
Anti-dilutive stock options excluded from computation of diluted earning per share	276,654	0

Summary_Revolving_Line_of_Cred

Summary Revolving Line of Credit And Various Notes Payable Constitute Short-Term and Long-Term Loan Balances Together (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Extinguishment of Debt [Line Items]
Indebtedness, Long-term	$85,036	$99,455
Indebtedness, Short-term	272	71
Revolving Line of Credit
Extinguishment of Debt [Line Items]
Indebtedness, Long-term	85,000	99,400
Total indebtedness	85,000	99,400
Notes payable
Extinguishment of Debt [Line Items]
Indebtedness, Long-term	36	55
Indebtedness, Short-term	272	71
Total indebtedness	308	126
Debt
Extinguishment of Debt [Line Items]
Indebtedness, Long-term	85,036	99,455
Indebtedness, Short-term	272	71
Total indebtedness	$85,308	$99,526

Indebtedness_Additional_Inform

Indebtedness - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Debt Instrument [Line Items]
Available borrowings capacity under credit agreement		$87,814,000
Senior secured credit facility term	5 years
Duration of losses in other comprehensive income expected to be reclassified to earnings	12 months
Maximum
Debt Instrument [Line Items]
Capacity to increase borrowings under credit agreement	22,710,000
Term Loan | Maximum
Debt Instrument [Line Items]
Accordion feature	100,000,000
Revolving Line of Credit
Debt Instrument [Line Items]
Available borrowings capacity under credit agreement	200,000,000
Cash Flow Hedging | Interest Rate Swap
Debt Instrument [Line Items]
Gains (losses) in other comprehensive income expected to be reclassified to earnings	0

Summary_of_Effect_of_Derivativ

Summary of Effect of Derivative Instruments on Statements of Operations (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain or (Loss) Recognized in OCI on Derivative (Effective Portion)		($23)
Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income (Effective Portion)	0	-159
Amount of Gain or (Loss) Recognized in Income on Derivative (Ineffective Portion)	0	0
Designated as Hedging | Cash Flow Hedging | Interest Rate Contracts
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain or (Loss) Recognized in OCI on Derivative (Effective Portion)		-23
Designated as Hedging | Cash Flow Hedging | Interest Rate Contracts | Interest Expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income (Effective Portion)	0	-159
Amount of Gain or (Loss) Recognized in Income on Derivative (Ineffective Portion)	$0	$0

Summary_of_Option_Activity_Det

Summary of Option Activity (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incentive Stock Option Plans, Beginning balance	724,904
Incentive Stock Option Plans, Option exercised	-16,650
Incentive Stock Option Plans, Option forfeited	-10,400
Incentive Stock Option Plans, Ending balance	697,854
Weighted Average Price Per Share, Beginning balance	$9.22
Weighted Average Price Per Share, Option exercised	$7.50
Weighted Average Price Per Share, Option forfeited	$11.49
Weighted Average Price Per Share, Ending balance	$9.21
Exercisable Weighted Average Price Per Share, Beginning balance	$7.82
Exercisable Weighted Average Price Per Share, Ending balance	$7.71
Performance Incentive Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incentive Stock Option Plans, Beginning balance		107,689
Incentive Stock Option Plans, Ending balance	107,689	107,689
Weighted Average Price Per Share, Beginning balance		$11.49
Weighted Average Price Per Share, Ending balance	$11.49	$11.49

Summary_of_Option_Activity_Par

Summary of Option Activity (Parenthetical) (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Price Per Share, Option exercised	$7.50
Weighted Average Price Per Share, Option forfeited	$11.49
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Price Per Share, Option forfeited	$11.49
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Price Per Share, Option forfeited	$13.24

Summary_of_Stock_Options_Summa

Summary of Stock Options Summarized by Exercise Price (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Weighted Average, Exercise Price	$9.21	$9.22
Exercisable Weighted Average, Exercise Price	$7.71	$7.82
Incentive Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Weighted Average, Shares	697,854
Outstanding Weighted Average, Remaining Life (Months)	87 months
Outstanding Weighted Average, Exercise Price	$9.21
Exercisable Weighted Average, Shares	421,229
Exercisable Weighted Average, Exercise Price	$7.71
Incentive Stock Option Plan | Range One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Per Share, Lower Range	$7.50
Outstanding Weighted Average, Shares	404,550
Outstanding Weighted Average, Remaining Life (Months)	68 months
Outstanding Weighted Average, Exercise Price	$7.50
Exercisable Weighted Average, Shares	404,550
Exercisable Weighted Average, Exercise Price	$7.50
Incentive Stock Option Plan | Range Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Per Share, Lower Range	$11.32
Exercise Price Per Share, Upper Range	$14.75
Outstanding Weighted Average, Shares	293,304
Outstanding Weighted Average, Remaining Life (Months)	114 months
Outstanding Weighted Average, Exercise Price	$11.56
Exercisable Weighted Average, Shares	16,679
Exercisable Weighted Average, Exercise Price	$12.69
Performance Incentive Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Weighted Average, Shares	107,689
Outstanding Weighted Average, Remaining Life (Months)	33 months
Outstanding Weighted Average, Exercise Price	$11.49	$11.49
Performance Incentive Stock Option Plan | Range Three
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price Per Share, Lower Range	$11.49
Outstanding Weighted Average, Shares	107,689
Outstanding Weighted Average, Remaining Life (Months)	33 months
Outstanding Weighted Average, Exercise Price	$11.49

Weighted_Average_Exercise_Pric

Weighted Average Exercise Prices for Options Granted and Exercisable and Weighted Average Remaining Contractual Life for Options Outstanding (Detail) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding	697,854	724,904
Weighted Average Exercise Price, Outstanding	$9.21	$9.22
Weighted Average Exercisable, Exercise Price	$7.71	$7.82
Incentive Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding	697,854
Number of Shares, Expected to Vest	686,973
Number of Shares, Exercisable	421,229
Weighted Average Exercise Price, Outstanding	$9.21
Weighted Average Exercise Price, Expected to Vest	$9.17
Weighted Average Exercisable, Exercise Price	$7.71
Weighted Average Remaining Life, Outstanding	87 months
Weighted Average Remaining Contractual Life, Expected to Vest	89 months
Weighted Average Remaining Contractual Life, Exercisable	71 months
Intrinsic Value, Outstanding	$1,262
Intrinsic Value, Expected to Vest	1,262
Intrinsic Value, Exercisable	$1,262
Performance Incentive Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding	107,689	107,689
Number of Shares, Expected to Vest	107,689
Weighted Average Exercise Price, Outstanding	$11.49	$11.49
Weighted Average Exercise Price, Expected to Vest	$11.49
Weighted Average Remaining Life, Outstanding	33 months
Weighted Average Remaining Contractual Life, Expected to Vest	33 months
Weighted Average Remaining Contractual Life, Exercisable	0 months

Stock_Based_Compensation_Expen2

Stock Based Compensation Expense - Additional Information (Detail) (USD $)	3 Months Ended		12 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding	697,854		724,904
Common Stock Issued	31,562,678		31,550,477
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$115	$11
Nonvested unamortized stock-based compensation expense, value	1,336
Nonvested unamortized stock-based compensation expense, contractual term	2 years 8 months 12 days
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	1,172	834
Nonvested unamortized stock-based compensation expense, contractual term	1 year 3 months 18 days
Number of Shares, Granted	30,000	0
Number of Shares, Vested	192,266
Weighted Average Grant-Date Fair Value, Granted	$11.42
Number of Shares, Forfeited	422
Weighted Average Grant-Date Fair Value, Forfeited	$14.92
Nonvested unamortized stock-based compensation expense other than options, value	4,010
Restricted Stock | Vest after 90 Days
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Vested	7,500
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	98	77
Nonvested unamortized stock-based compensation expense, contractual term	1 year 10 months 24 days
Number of Shares, Granted	7,500		0
Number of Shares, Vested	0
Weighted Average Grant-Date Fair Value, Granted	$10.96
Number of Shares, Forfeited	0
Weighted Average Grant-Date Fair Value, Forfeited	$0
Nonvested unamortized stock-based compensation expense other than options, value	917
Cliff vesting date	5-Jan-18
Targeted performance percentage	200.00%
Performance Shares | Performance Based Shares Based Upon Financial Performance of Earnings before Interest Tax ("EBIT") and Net Sales Goal for the Period Commencing January 1, 2015 and Ending December 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of shares vesting based on Performance	80.00%
Earnings before income tax goal weight, percentage	50.00%
Net sales goal weight, percentage	30.00%
Performance Shares | Performance Based Shares Based Upon AVD Stock Price Appreciation Over the Course of the Period Commencing January 1, 2015, Ending December 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of shares vesting based on Performance	20.00%
Performance Shares | Performance Based Shares Related to Net Income Weighted at 50%, Net Sales Weighted at 30%, Commencing January 1, 2015 and Ending December 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Grant-Date Fair Value, Granted	$11.42
Performance Shares | Remaining 20% of Performance Based Shares are Based Upon AVD Stock Price Appreciation for the Period Commencing January 1, 2015 and Ending December 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Grant-Date Fair Value, Granted	$9.13
Performance Incentive Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding	107,689		107,689
Number of Shares, Expected to Vest	107,689
Stock-based compensation expense	42
Nonvested unamortized stock-based compensation expense, contractual term	2 years 9 months 18 days
Nonvested unamortized stock-based compensation expense other than options, value	499
Common Stock Issued			0
Incentive Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Intrinsic Value, Outstanding	$1,262
Publicly traded closing price per share	$10.62
Number of Shares, Outstanding	697,854
Number of Shares, Expected to Vest	686,973
Number of Shares, Exercisable	421,229
Incentive Stock Option Plan | Shares Priced below Closing Market Price
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding	404,550,000
Number of Shares, Expected to Vest	404,550,000
Number of Shares, Exercisable	404,550,000
Incentive Stock Option Plan | Shares Priced above Closing Market Price
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding	293,304,000
Number of Shares, Expected to Vest	282,423,000
Number of Shares, Exercisable	16,679,000

Summary_of_NonVested_Shares_De

Summary of Non-Vested Shares (Detail) (Restricted Stock, USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Beginning balance	560,842
Number of Shares, Granted	30,000	0
Number of Shares, Vested	-192,266
Number of Shares, Forfeited	-422
Number of Shares, Ending Balance	398,154
Weighted Average Grant-Date Fair Value, Beginning balance	$21.44
Weighted Average Grant-Date Fair Value, Granted	$11.42
Weighted Average Grant-Date Fair Value, Vested	$20.47
Weighted Average Grant-Date Fair Value, Forfeited	$14.92
Weighted Average Grant-Date Fair Value, Ending balance	$21.17

Status_Summary_of_NonVested_Sh

Status Summary of Non-Vested Shares (Detail) (Performance Shares, USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Beginning balance	103,907
Number of Shares, Granted	7,500	0
Number of Shares, Vested	0
Number of Shares, Forfeited	0
Number of Shares, Ending Balance	111,407	103,907
Weighted Average Grant-Date Fair Value, Beginning balance	$17.81
Weighted Average Grant-Date Fair Value, Granted	$10.96
Weighted Average Grant-Date Fair Value, Vested	$0
Weighted Average Grant-Date Fair Value, Forfeited	$0
Weighted Average Grant-Date Fair Value, Ending balance	$17.35	$17.81

Beginning_Balance_Annual_Activ

Beginning Balance, Annual Activity and Ending Balance of Accumulated Other Comprehensive Income (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance		($1,970)
Ending Balance	-2,218	-1,970
Accumulated Translation Adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	-1,970
Other comprehensive loss	-248
Ending Balance	($2,218)

Equity_Investment_Additional_I

Equity Investment - Additional Information (Detail)	0 Months Ended	3 Months Ended			1 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 25, 2013	Mar. 31, 2015	Mar. 31, 2014	Mar. 25, 2013	Feb. 28, 2014	Feb. 28, 2014
	USD ($)	USD ($)	USD ($)		TyraTech Inc.	TyraTech Inc.
					USD ($)	GBP (£)
Equity Method Investments [Line Items]
Equity investment	$3,687
Shares issued by equity investee					37,391,763	37,391,763
Amount raised by equity investee on shares issued					3,100	1,870
Gain on dilution of equity method investment			256
Equity investment ownership position		21.18%		29.27%
Gain loss from equity method investment		0	-328
Carrying value of equity investment		3,172
Quoted market value of equity investment		$3,914

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Income Taxes [Line Items]
Income taxes (benefit) expense	($292)	$1,016
Effective tax rate	87.20%	30.00%

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Detail)	Mar. 31, 2015	Mar. 25, 2013	Apr. 01, 2015
Subsequent Event [Line Items]
Equity investment ownership position	21.18%	29.27%
Subsequent Event | Envance Technologies, LLC] | Before Amendment
Subsequent Event [Line Items]
Equity investment ownership position			60.00%
Subsequent Event | Envance Technologies, LLC] | After Amendment
Subsequent Event [Line Items]
Equity investment ownership position			87.00%